Targeted therapies against ROS1-rearrangements cancer face limitations. Ma et al. report that a next-generation, brain-penetrant ROS1 inhibitor, JYP0322, achieved high response rates in patients with ROS1-positive non-small cell lung cancer, including heavily pretreated patients and those with brain metastases or resistance mutations, while showing manageable toxicity.
Cancer Cell published a clinical update in Oncology on 23 Apr 2026.
The item focuses on JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1G2032R resistance mutation in NSCLC: The first-in-human phase 1 trial.
Review the original article for the full source wording and details.